Brazilian Protocol for Sexually Transmitted Infections 2020: human T-cell lymphotropic virus (HTLV) infection.
Carolina RosadasCarlos BritesDenise Arakaki-SanchezJorge Simão do Rosário CassebRicardo IshakPublished in: Revista da Sociedade Brasileira de Medicina Tropical (2021)
This article addresses the Human T-lymphotropic virus (HTLV). This subject comprises the Clinical Protocol and Therapeutic Guidelines for Comprehensive Care for People with Sexually Transmitted Infections, published by the Brazilian Ministry of Health. HTLV-1/2 infection is a public health problem globally, and Brazil has the largest number of individuals living with the virus. HTLV-1 causes several clinical manifestations of neoplasm (adult T-cell leukemia/lymphoma) and inflammatory nature, such as HTLV-1-associated myelopathy and other manifestations such as uveitis, arthritis, and infective dermatitis. These pathologies have high morbidity and mortality and negatively impact the quality of life of infected individuals. This review includes relevant information for health authorities professionals regarding viral transmission, diagnosis, treatment, and monitoring of individuals living with HTLV-1 and 2 in Brazil. HTLV-1/2 transmission can occur through blood transfusion and derivatives, injectable drug use, organ transplantation, unprotected sexual intercourse, and vertical transmission.
Keyphrases
- public health
- healthcare
- endothelial cells
- mental health
- randomized controlled trial
- rheumatoid arthritis
- health information
- palliative care
- sars cov
- spinal cord
- pluripotent stem cells
- systematic review
- diffuse large b cell lymphoma
- low grade
- global health
- oxidative stress
- health insurance
- ankylosing spondylitis
- juvenile idiopathic arthritis
- mesenchymal stem cells
- affordable care act
- health promotion
- climate change
- atopic dermatitis
- disease virus
- finite element